Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

β-Decay Half-Lives of Neutron-Rich Sulfur to Potassium: Evolution of the N=32 and 34 Subshell Closures below Calcium.

Physical review letters·2025
Same author

Bridging the Gap: Managing Hypertension in Indian Patients with Metabolic Syndrome.

The Journal of the Association of Physicians of India..·2025
Same author

A large multicenter cohort on the use of full-thickness resection device for difficult colonic lesions.

Surgical endoscopy·2020
Same author

Feasibility of collecting tumor samples of breast cancer patients diagnosed up to 50 years ago in the Child Health and Development Studies.

Journal of developmental origins of health and disease·2017
Same author

RMS Pictorial Scale (RMS-PS): an innovative scale for the assessment of child's dental anxiety.

Journal of the Indian Society of Pedodontics and Preventive Dentistry·2015
Same author

Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.

British journal of pharmacology·2013
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K

Ursodiol for hepatobiliary disorders

R A Rubin1, T E Kowalski, M Khandelwal

  • 1Jefferson Medical College, Philadelphia, Pennsylvania.

Annals of Internal Medicine
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Ursodiol (ursodeoxycholic acid) effectively dissolves cholesterol gallstones and improves liver disease markers. It is a safe and well-tolerated treatment option for patients with these conditions.

More Related Videos

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.1K
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

615

Related Experiment Videos

Last Updated: May 5, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.1K
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

615

Area of Science:

  • Hepatology and Gastroenterology
  • Pharmacology
  • Bile Acid Therapy

Background:

  • Cholesterol gallstones and chronic liver diseases pose significant health challenges.
  • Ursodiol (ursodeoxycholic acid) is a naturally occurring bile acid with therapeutic potential.
  • Understanding its efficacy and safety is crucial for clinical practice.

Purpose of the Study:

  • To review the rationale for using ursodiol in treating cholesterol gallstones.
  • To evaluate ursodiol's effectiveness in chronic liver diseases.
  • To summarize clinical trial outcomes for ursodiol therapy.

Main Methods:

  • Literature search of personal databases and MEDLINE for English-language articles.
  • Emphasis on randomized controlled trials (RCTs) for cholesterol gallstones and liver diseases.
  • Meta-analysis of relevant RCTs to determine dissolution rates.

Main Results:

  • Ursodiol demonstrates comparable efficacy to chenodiol for gallstone dissolution with fewer side effects.
  • Effective dissolution rates (30-50%) observed for stones <20 mm, particularly small, buoyant ones.
  • Ursodiol improves cholestasis and inflammation markers in liver diseases, with relief of pruritus.

Conclusions:

  • Ursodiol is a safe and effective treatment for cholesterol gallstones.
  • It offers biochemical improvements in cholestatic liver diseases, but long-term impact requires further investigation.
  • Ongoing trials will clarify ursodiol's role in altering the natural history of liver disorders.